Table 1 Baseline characteristics of the subject participants
Variable (n = 83) | Value |
|---|---|
Age, y.o | 55 (49–60) |
Sex | |
Male, n (%) | 45 (55.6) |
Female, n (%) | 36 (44.4) |
Smoking, n (%) | |
Active smoker, n (%) | 6 (7.4) |
Former smoker, n (%) | 24 (29.6) |
Never smoker, n (%) | 51 (63) |
DM duration, years | 6 (3–11) |
History of hypertension, n (%) | 52 (64.2) |
History of dyslipidemia, n (%) | 48 (59.3) |
DM complication: | 44 (54.3) |
Coronary artery disease, n (%) | 28 (34.6) |
Chronic heart failure, n (%) | 7 (8.6) |
Stroke, n (%) | 9 (11.1) |
Diabetic retinopathy, n (%) | 13 (16) |
Body mass index, kg/m2 | 24.78 ± 3.79 |
Systolic blood pressure, mmHg | 141.12 ± 20.49 |
Pulse pressure, mmHg | 58.36 ± 15.36 |
Treatment parameter | |
Statin, n (%) | 48 (59.3) |
Low intensity statin, n (%) | 17 (21) |
Moderate intensity statin, n (%) | 28 (34.6) |
High intensity statin, n (%) | 3 (3.7) |
High intensity statin + ezetimibe, n (%) | 0 |
Statin duration, years | 0.083 (0–1.5) |
ACE inhibitor/ARB, n (%) | 46 (56.8) |
Vitamin, n (%) | 40 (49.4) |
Antidiabetic drugs: | 79 (97.5) |
Oral anti diabetic drugs, n (%) | 35 (43.2) |
Insulin, n (%) | 27 (33.3) |
Combination of oral and insulin, n (%) | 17 (21) |
Nitrate, n (%) | 11 (13.6) |
NSAID, n (%) | 32 (38.3) |
Artery examination parameter | |
ABI | 1.05 ± 0.076 |
CAVI | 8.14 ± 0.93 |
Laboratory parameter | |
Leucocyte count, × 103/μL | 8.06 ± 2.05 |
Monocyte count, × 103/ μL | 0.53 (0.46–0.64) |
Fasting blood glucose, mg/dL | 151 (113–210) |
HDL cholesterol, mg/dL | 43 (38–50) |
LDL cholesterol, mg/dL | 133.75 ± 41.68 |
LDL ≥ 160 mg/dL, n (%) | 23 (28.4) |
HbA1c, % | 8.56 ± 1.98 |
HbA1c ≥ 7%, n (%) | 58 (71.6) |
Monocyte to HDL ratio (MHR) | 12.56 (9.62–15.53) |
Creatinine, mg/dL | 0.89 ± 0.2 |
Estimated GFR, mL/min/1.73 m2 | 84.35 (71.51–101.09) |